|開催日時：||2019年9月20日 １６：００ ～ １７：３０|
|講師：||David I Watkins|
|所属：||Professor, Department of Pathology,
University of Miami Medical School, USA
|演題：||Neutralizing monoclonal antibodies to prevent and treat Zika, dengue and yellow fever virus infection.|
Nearly one billion people are at risk of wild type yellow fever infection (wtYFV), and up to 50% of the symptomatic wtYFV-infected patients will die. Most of the world, and the US, are vulnerable to mosquito-transmitted diseases, as shown by the emergence of two related Flaviviruses, dengue (DENV) and Zika (ZIKV). Our laboratory has assembled several Flavivirus-specific neutralizing monoclonal antibodies (nmAbs). We have already shown that these mAbs can be used for the prevention and treatment of Flaviviruses and have demonstrated that ZIKV infection can be prevented in Indian rhesus macaques by using a cocktail of nmAbs. More importantly we have also showed that this nmAb cocktail can reduce viral load to undetectable levels in ZIKV-infected pregnant macaques. Post-infection treatment with nmAbs can, therefore, reduce Flavivirus replication in a relevant non-human primate (NHP) model. We are proposing to build on our earlier work to create novel nmAb-based preventative and therapeutic approaches to both prevent wtYFV infection and to reduce viral replication after infection. These nmAbs could play an important role in ameliorating suffering from this fatal virus by preventing virus-induced morbidity, transmission, and the high mortality rate of this disease. Furthermore, these nmAbs might also prevent vaccine-induced mortality, increasing the safety and therefore, the palatability of the YFV17D vaccine for the population.
|世話人：||〇俣野 哲朗 （エイズワクチン開発担当）
四柳 宏 （感染症分野）